Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events

Cost-effectiveness model structure. Cost-effectiveness model structure comparing aspirin adherence vs aspirin non-adherence for secondary prevention of CV events. At the decision node (□), patients were assigned as being adherent or non-adherent to aspirin based on the rate found in the literature. Patients entered the decision node with a prior CV event. In each 1-year cycle, patients may experience an event (non-fatal or fatal) or no event if they are alive. This model was applied to a population without co-morbidity (non-diabetic model) and a population with type II diabetes (type II diabetes model). CV cardiovascular, GI gastrointestinal, MI myocardial infarction, PAD peripheral arterial diseas